Navigation Links
Cell Genesys to Present at the BIO CEO and Investor Conference
Date:2/4/2008

SOUTH SAN FRANCISCO, Calif., Feb. 4 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (Nasdaq: CEGE) today announced that Stephen A. Sherwin, M.D., chairman and chief executive officer of Cell Genesys, will present a company update at the BIO CEO and Investor Conference in New York, New York, on Monday, February 11, 2008 at 11:00 a.m. ET.

A live audio webcast of the presentation will be accessible through the Investor Relations section of the Cell Genesys website, http://www.cellgenesys.com. If you are unable to listen to the live webcast, it will be archived on the site for at least 72 hours following the presentation. To access the replay, go to the Investor Relations section of the website.

Cell Genesys is focused on the development and commercialization of novel biological therapies for patients with cancer. The company is currently pursuing two clinical stage product platforms -- GVAX(TM) cancer immunotherapies and oncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of GVAX immunotherapy for prostate cancer, Phase 2 trials of GVAX immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial of CG0070 oncolytic virus therapy for bladder cancer. Cell Genesys continues to hold an equity interest in its former subsidiary, Ceregene, Inc., which is developing gene therapies for neurodegenerative disorders. Cell Genesys is headquartered in South San Francisco, CA and has its principal manufacturing operation in Hayward, CA. For additional information, please visit the company's website at http://www.cellgenesys.com.

Contact:

Susan Ferris

Investor Relations'/>"/>

SOURCE Cell Genesys
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cell Genesys to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Cell Genesys to Present at the BIO Investor Forum
3. Cell Genesys to Webcast Third Quarter 2007 Conference Call
4. Cell Genesys Announces Sale of Lentiviral Gene Delivery Technology for $12 Million
5. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
6. Avicena Group to Present at Noble Financial Conference
7. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
8. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
9. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
10. CEL-SCI to Present at the Noble Financial Conference
11. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... CORAL SPRINGS, Florida , August 26, 2015 ... one of the biggest factors fueling the optimism ... FDA approvals, M&A,s, collaborations and life sciences advancements.  ... and developments are Pressure BioSciences, Inc. (OTCQB: PBIO), ... Inc. (NASDAQ: SRPT ), Raptor Pharmaceutical Corp. ...
(Date:8/25/2015)... ... August 25, 2015 , ... A new ... cancerous is described by University of Illinois researchers in the Journal of ... , In “ Breast cancer diagnosis using spatial light interference microscopy ,” published ...
(Date:8/25/2015)... ... August 25, 2015 , ... ... blade-based and rackmount computing infrastructure, today announced the launch of its next ... The latest system boasts two distinct, individually sledded workstation nodes in each ...
(Date:8/25/2015)... KING OF PRUSSIA, Pa. , Aug. 25, 2015 ... first patient has been enrolled in its Phase II/III ... of the company,s recombinant fusion protein linking coagulation factor ... with congenital hemophilia A or B who have developed ... therapy. The study will enroll approximately 54 male patients, ...
Breaking Biology Technology:New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 2New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 4New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 5New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 6New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 7New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 2New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 3New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 4Cirrascale® Announces Next Generation High Density, Two-in-One GPU Rackmount Offering Perfect for High Performance Remote Workstations 2Cirrascale® Announces Next Generation High Density, Two-in-One GPU Rackmount Offering Perfect for High Performance Remote Workstations 3CSL Behring Enrolls First Patient in Global Phase II/III Study of rVIIa-FP for On-Demand Treatment of Patients with Hemophilia A or B with Inhibitors 2CSL Behring Enrolls First Patient in Global Phase II/III Study of rVIIa-FP for On-Demand Treatment of Patients with Hemophilia A or B with Inhibitors 3CSL Behring Enrolls First Patient in Global Phase II/III Study of rVIIa-FP for On-Demand Treatment of Patients with Hemophilia A or B with Inhibitors 4
... Iowa and the University of Missouri (MU) have developed a ... mimic the disease in human infants. The striking similarities between ... CF suggest that this new model will help improve understanding ... treatments. The study is published in the Sept. 26 issue ...
... More efficient. These are the qualities that drive science ... help to speed up computers. , Scientists at the ... contribution to this field by designing a new nanotechnology ... more efficient. The new process is described in today,s ...
... Scientific Accomplishment in Complement Inhibition and,Impact of Soliris ... Sept. 25 Alexion,Pharmaceuticals, Inc. (Nasdaq: ALXN ... for Best Biotechnology Product for Soliris(R) (eculizumab). The ... of Soliris, and the impact the drug is,having ...
Cached Biology Technology:Researchers develop new model for cystic fibrosis 2New nanoscale process created by UCSB scientists will help computers run faster and more efficiently 2New nanoscale process created by UCSB scientists will help computers run faster and more efficiently 3New nanoscale process created by UCSB scientists will help computers run faster and more efficiently 4New nanoscale process created by UCSB scientists will help computers run faster and more efficiently 5Alexion's Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product 2Alexion's Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product 3Alexion's Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product 4Alexion's Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product 5
(Date:8/5/2015)... , August 5, 2015 ... & Access Management Market by Software, Services, Vertical (BFSI, Airport, ... & Geography - Global Forecast to 2020", published by ... Management Market globally into various segments. The global PIAM ... 2014 to $546.2 Million by 2019, at a CAGR ...
(Date:8/3/2015)... Aug. 3, 2015 Synaptics, Inc. (Nasdaq: ... today announced that members of the executive management team ... Crest Global Technology Leadership Forum on Tuesday, August 11, ... be held at the Sonnenalp Resort in ... may include forward-looking information. An audio webcast of the ...
(Date:7/31/2015)... SHENZHEN, China , 31 de julio de 2015 /PRNewswire/ ... www.icg-10.org ) se celebrará por medio de BGI del 22 ... China . Este año, la conferencia ... 2006, ICG se ha convertido en una de las reuniones ... de ser una de las reuniones más dinámicas, entusiastas y ...
Breaking Biology News(10 mins):Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3
... The Office of Naval Research (ONR) has awarded a ... from Boston University, the University of Washington, the University ... Chapel Hill. The grant will fund a project entitled ... Strategies), which will focus on the development of unmanned ...
... Cooperation across borders and disciplines is essential ... and substantial economic damages. In 2008 Myanmar in the Indian ... associated storm surge left a trail of destruction. More than ... Netherlands, England, and Hamburg were severely affected by storm surges. ...
... spruce and mountain pine beetles in western North America,s ... decades, according to a study conducted by USDA Forest ... the September issue of the journal BioScience , ... climate change on bark beetles. "Native bark ...
Cached Biology News:BU partners in 5-year, $7.5M grant to study animal flight 2Storm Surges Congress 2010 -- scientists from 30 countries meet in Hamburg 2Risk of beetle outbreaks rise, along with temperature, in the warming West 2
Umbilical cord blood mononuclear cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood MNCs and T Cells...
Human peripheral blood basophils, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Granulocytes...
Human peripheral blood CD8+ T cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood PBMC and T Cells...
... been developed specifically for the stabilization ... microwell plates/strips. Coating Stabilizer maintains ... antibody or protein antigen portion of ... is filtered at 0.2 microns., ,Contents: ...
Biology Products: